Latest News


Filter by tags: Iodine-131 Clear all tag filters

37 news articles found

Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.

Date: Friday, 27 January 2023
Original article:

The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.

Date: Wednesday, 25 January 2023
Original article:

Belgium's SCK-CEN nuclear research centre has received all the licences needed for the construction and operation of a facility to support the RECUMO project to manage and recycle radioactive residues from the production of medical radioisotopes.

Date: Saturday, 05 March 2022
Original article:

SHINE Technologies of the USA has announced its European subsidiary, SHINE Europe, has secured funding to begin designing an advanced medical isotope production facility at Veendam in the Netherlands.

Date: Thursday, 03 February 2022
Original article:

The South African Nuclear Energy Corporation (Necsa) issued a statement on 26 September welcoming the Cabinet’s decision to approve the acquisition and construction of a new Multipurpose Reactor (MPR).

Date: Tuesday, 05 October 2021
Original article:

Isotop JSC (part of Rusatom Healthcare, Rosatom’s radiation technologies integrator) on 9 June signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN, part of the National Nuclear Energy Commission, CNEN) to supply medical isotopes lutetium-177 and actinium-225.

Date: Friday, 11 June 2021
Original article:

The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) on 9 March released its 2020 Report, “Levels and effects of radiation exposure due to the accident at the Fukushima Daiichi Nuclear Power Station: Implications of information published since the UNSCEAR 2013 Report”. UNSCEAR Chair Gillian Hirth noted: “Since the UNSCEAR 2013 Report, no adverse health effects among Fukushima residents have been documented that could be directly attributed to radiation exposure from the accident.” Twelve UNSCEAR Member States and one observer contributed with over 30 experts to the 2020 evaluation.

Date: Friday, 12 March 2021
Original article:

Scientists at Russia’s DI Mendeleev University of Chemical Technology (MUCTR) have developed a new technology for the manufacture of a sorbent for the elusive form of radioactive iodine - methyl iodide.

Date: Thursday, 21 January 2021
Original article:

Of the 220 research reactors in operation today, only seven are on the African continent. In other words, with 17.2% of the world population and the strongest expected growth in the coming years, Africans have access to only 3% of the world's nuclear research reactor capacity. Marguerite Leonardi, senior advisor at NPC Consulting & Engineering, and Professor Vincent Lukanda Mwamba, Commissaire Général of the Commissariat Général à l’Energie Atomique, explain why that is a concern and why the research reactor in Kinshasa should be restarted urgently.

Date: Tuesday, 13 October 2020
Original article:

Rusatom Healthcare, part of state nuclear corporation Rosatom, will build Russia’s first radiopharmaceutical plant to meet global GMP good manufacturing practice standards. The new production facility will be in Obninsk at the site of LYa Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) and will produce drugs for targeted cancer therapy. The design of pharmaceutical production will be carried out by the Central Design and Technological Institute. Pre-design work is planned to be completed this year, for commissioning in 2024  production in early 2025.

Date: Friday, 07 August 2020
Original article: